Lipids and the pathogenesis of Alzheimer's disease: Is there a link?

References

• Abad-Rodriguez J, Ledesma MD, Craessaerts K, Perga S, Medina M, Delacourte A, et al. Neuronal membrane cholesterol loss enhances amyloid peptide generation. Journal of Cell Biology 2004; 167: 953–960
   PubMed Web of Science ®Google Scholar
• Andrieu-Abadie N, Gouaze V, Salvayre R, Levade T. Ceramide in apoptosis signaling: Relationship with oxidative stress. Free Radical Biology and Medicine 2001; 31: 717–728
   PubMed Web of Science ®Google Scholar
• Auestad N. Infant nutrition—brain development—disease in later life. An introduction. Developmental Neuroscience 2000; 22: 472–473
   PubMed Web of Science ®Google Scholar
• Barany M, Chang YC, Arus C, Rustan T, Frey WH. Increased glycerol-3-phosphorylcholine in post-mortem Alzheimer's brain. Lancet 1985; 1(8427)517
   PubMedGoogle Scholar
• Barenholz Y. Cholesterol and other membrane active sterols: From membrane evolution to ‘rafts’. Progress in Lipid Research 2002; 41: 1–5
   PubMed Web of Science ®Google Scholar
• Beffert U, Poirier J. Apolipoprotein E, plaques, tangles and cholinergic dysfunction in Alzheimer's disease. Annals of the New York Academy of Sciences 1996; 777: 166–174
   PubMedGoogle Scholar
• Bjorkhem I, Lutjohann D, Diczfalusy U, Stahle L, Ahlborg G, Wahren J. Cholesterol homeostasis in human brain: Turnover of 24S-hydroxycholesterol and evidence for a cerebral origin of most of this oxysterol in the circulation. Journal of Lipid Research 1998; 39: 1594–1600
   PubMed Web of Science ®Google Scholar
• Bjorkhem I, Meaney S. Brain cholesterol: Long secret life behind a barrier. Arteriosclerosis Thrombosis and Vascular Biology 2004; 24: 806–815
   PubMed Web of Science ®Google Scholar
• Boyles JK, Zoellner CD, Anderson LJ, Kosik LM, Pitas RE, Weisgraber KH, et al. A role for apolipoprotein E, apolipoprotein A-I, and low density lipoprotein receptors in cholesterol transport during regeneration and remyelination of the rat sciatic nerve. Journal of Clinical Investigation 1989; 83: 1015–1031
   PubMed Web of Science ®Google Scholar
• Bretillon L, Siden A, Wahlund LO, Lutjohann D, Minthon L, Crisby M, et al. Plasma levels of 24S-hydroxycholesterol in patients with neurological diseases. Neuroscience Letters 2000; 293: 87–90
   PubMed Web of Science ®Google Scholar
• Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. American Journal of Public Health 1998; 88: 1337–1342
   PubMed Web of Science ®Google Scholar
• Brown DA, London E. Structure and function of sphingolipid- and cholesterol-rich membrane rafts. Journal of Biological Chemistry 2000; 275: 17221–17224
   PubMed Web of Science ®Google Scholar
• Busciglio J, Yankner BA. Apoptosis and increased generation of reactive oxygen species in Down's syndrome neurons in vitro. Nature 1995; 378: 776–779
   PubMed Web of Science ®Google Scholar
• Choe M, Jackson C, Yu BP. Lipid peroxidation contributes to age-related membrane rigidity. Free Radical Biology and Medicine 1995; 18: 977–984
   PubMed Web of Science ®Google Scholar
• Clarke SD. Polyunsaturated fatty acid regulation of gene transcription: A molecular mechanism to improve the metabolic syndrome. The Journal of Nutrition 2001; 131: 1129–1132
   PubMed Web of Science ®Google Scholar
• Combarros O, Infante J, Llorca J, Berciano J. Genetic association of CYP46 and risk for Alzheimer's disease. Dementia and Geriatric Cognitive Disorders 2004; 18: 257–260
   PubMedGoogle Scholar
• Conquer JA, Tierney MC, Zecevic J, Bettger WJ, Fisher RH. Fatty acid analysis of blood plasma of patients with Alzheimer's disease, other types of dementia, and cognitive impairment. Lipids 2000; 35: 1305–1312
   PubMed Web of Science ®Google Scholar
• Cummings JL, Vinters HV, Cole GM, Khachaturian ZS. Alzheimer's disease: Etiologies, pathophysiology, cognitive reserve, and treatment opportunities. Neurology 1998; 51: S2–S17
   PubMed Web of Science ®Google Scholar
• Cutler RG, Haughey NJ, Tammara A, McArthur JC, Nath A, Reid R, et al. Dysregulation of sphingolipid and sterol metabolism by ApoE4 in HIV dementia. Neurology 2004; 63: 626–630
   PubMedGoogle Scholar
• Cutler RG, Mattson MP. Sphingomyelin and ceramide as regulators of development and lifespan. Mechanisms of Ageing and Development 2001; 122: 895–908
   PubMed Web of Science ®Google Scholar
• Chaves EI, Rusinol AE, Vance DE, Campenot RB, Vance JE. Role of lipoproteins in the delivery of lipids to axons during axonal regeneration. The Journal of Biological Chemistry 1997; 272: 30766–30773
   PubMedGoogle Scholar
• Denisova NA, Fisher D, Provost M, Joseph JA. The role of glutathione, membrane sphingomyelin, and its metabolites in oxidative stress-induced calcium ‘dysregulation’ in PC12 cells. Free Radical Biology and Medicine 1999; 27: 1292–1301
   PubMed Web of Science ®Google Scholar
• Desai P, DeKosky ST, Kamboh MI. Genetic variation in the cholesterol 24-hydroxylase (CYP46) gene and the risk of Alzheimer's disease. Neuroscience Letters 2002; 328: 9–12
   PubMedGoogle Scholar
• Dietschy JM, Turley SD. Cholesterol metabolism in the brain. Current Opinion in Lipidology 2001; 12: 105–112
   PubMed Web of Science ®Google Scholar
• Dzeletovic S, Breuer O, Lund E, Diczfalusy U. Determination of cholesterol oxidation products in human plasma by isotope dilution-mass spectrometry. Analytical Biochemistry 1995; 225: 73–80
   PubMed Web of Science ®Google Scholar
• Ehehalt R, Keller P, Haass C, Thiele C, Simons K. Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts. The Journal of Cell Biology 2003; 160: 113–123
   PubMed Web of Science ®Google Scholar
• Esterbauer H, Schaur RJ, Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radical Biology and Medicine 1991; 11: 81–128
   PubMed Web of Science ®Google Scholar
• Fan QW, Yu W, Senda T, Yanagisawa K, Michikawa M. Cholesterol-dependent modulation of tau phosphorylation in cultured neurons. Journal of Neurochemistry 2001; 76: 391–400
   PubMedGoogle Scholar
• Farooqui AA, Ong WY, Horrocks LA. Biochemical aspects of neurodegeneration in human brain: Involvement of neural membrane phospholipids and phospholipases A2. Neurochemical Research 2004; 29: 1961–1977
   PubMedGoogle Scholar
• Fassbender K, Simons M, Bergmann C, Stroick M, Lutjohann D, Keller P, et al. Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proceedings of the National Academy of Sciences USA 2001; 98: 5856–5861
   PubMed Web of Science ®Google Scholar
• Feillet-Coudray C, Tourtauchaux R, Niculescu M, Rock E, Tauveron I, Alexandre-Gouabau MC, et al. Plasma levels of 8-epiPGF2alpha, an in vivo marker of oxidative stress, are not affected by aging or Alzheimer's disease. Free Radical Biology and Medicine 1999; 27: 463–469
   PubMed Web of Science ®Google Scholar
• Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, for Alzheimer Disease International. Global prevalence of dementia: A Delphi consensus study. Lancet 2005; 366: 2112–2117
   PubMed Web of Science ®Google Scholar
• Floyd RA. Antioxidants, oxidative stress, and degenerative neurological disorders. Proceedings of the Society for Experimental Biology and Medicine 1999; 222: 236–245
   PubMed Web of Science ®Google Scholar
• Giusto NM, Roque ME, Ilincheta de Boschero MG. Effects of aging on the content, composition and synthesis of sphingomyelin in the central nervous system. Lipids 1992; 27: 835–839
   PubMedGoogle Scholar
• Goodman Y, Mattson MP. Ceramide protects hippocampal neurons against excitotoxic and oxidative insults, and amyloid beta-peptide toxicity. Journal of Neurochemistry 1996; 66: 869–872
   PubMed Web of Science ®Google Scholar
• Growdon JH, Selkoe DJ, Roses A, Trojanowski JQ, Davies P, Appel S. Consensus report of the Working Group on Biological markers of Alzheimer's disease. [Ronald and Nancy Reagan Institute of the Alzheimer's Association and National Institute on Aging Working Group on Biological Markers of Alzheimer's Disease]. Neurobiology of Aging 1998; 19: 109–116
   PubMedGoogle Scholar
• Gustafson D, Rothenberg E, Blennow K, Steen B, Skoog I. An 18-year follow-up of overweight and risk of Alzheimer disease. Archives of Internal Medicine 2003; 163: 1524–1528
   PubMed Web of Science ®Google Scholar
• Hannun YA, Loomis CR, Merrill AH, Bell RM. Sphingosine inhibition of protein kinase C activity and of phorbol dibutyrate binding in vitro and in human platelets. The Journal of Biological Chemistry 1986; 261: 12604–12609
   PubMed Web of Science ®Google Scholar
• Hannun YA, Luberto C, Argraves KM. Enzymes of sphingolipid metabolism: From modular to integrative signaling. Biochemistry 2001; 40: 4893–4903
   PubMed Web of Science ®Google Scholar
• Harris WS. n-3 fatty acids and lipoproteins: Comparison of results from human and animal studies. Lipids 1996; 31: 243–252
   PubMed Web of Science ®Google Scholar
• Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA. Alzheimer disease in the US population: Prevalence estimates using the 2000 census. Archives of Neurology 2003; 60: 1119–1122
   PubMed Web of Science ®Google Scholar
• Hofman A, Ott A, Breteler MM, Bots ML, Slooter AJ, van Harskamp F, et al. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study. Lancet 1997; 349: 151–154
   PubMed Web of Science ®Google Scholar
• Honig LS, Tang MX, Albert S, Costa R, Luchsinger J, Manly J, et al. Stroke and the risk of Alzheimer's disease. Archives of Neurology 2003; 60: 1707–1712
   PubMedGoogle Scholar
• Ignatius MJ, Gebicke-Haerter PJ, Pitas RE, Shooter EM. Apolipoprotein E in nerve injury and repair. Progress in Brain Research 1987; 71: 177–184
   PubMedGoogle Scholar
• Ingelsson M, Jesneck J, Irizarry MC, Hyman BT, Rebeck GW. Lack of association of the cholesterol 24-hydroxylase (CYP46) intron 2 polymorphism with Alzheimer's disease. Neuroscience Letters 2004; 367: 228–231
   PubMedGoogle Scholar
• Irie F, Hirabayashi Y. Application of exogenous ceramide to cultured rat spinal motoneurons promotes survival or death by regulation of apoptosis depending on its concentrations. Journal of Neuroscience Research 1998; 54: 475–485
   PubMedGoogle Scholar
• Jarvis WD, Kolesnick RN, Fornari FA, Traylor RS, Gewirtz DA, Grant S. Induction of apoptotic DNA damage and cell death by activation of the sphingomyelin pathway. Proceedings of the National Academy of Sciences USA 1994; 91: 73–77
   PubMed Web of Science ®Google Scholar
• Jira PE, Waterham HR, Wanders RJ, Smeitink JA, Sengers RC, Wevers RA. Smith-Lemli-Opitz syndrome and the DHCR7 gene. Annals of Human Genetics 2003; 67: 269–280
   PubMedGoogle Scholar
• Jorm AF, Jolley D. The incidence of dementia: A meta-analysis. Neurology 1998; 51: 728–733
   PubMed Web of Science ®Google Scholar
• Jurevics H, Morell P. Cholesterol for synthesis of myelin is made locally, not imported into brain. Journal of Neurochemistry 1995; 64: 895–901
   PubMed Web of Science ®Google Scholar
• Kalmijn S, Foley D, White L, Burchfield CM, Curb JD, Petrovitch H, et al. Metabolic cardiovascular syndrome and risk of dementia in Japanese-American elderly men. The Honolulu-Asia aging study. Arteriosclerosis Thrombosis and Vascular Biology 2000; 20: 2255–2260
   PubMed Web of Science ®Google Scholar
• Kalmijn S, Launer LJ, Ott A, Witteman JC, Hofman A, Breteler MM. Dietary fat intake and the risk of incident dementia in the Rotterdam Study. Annals of Neurology 1997; 42: 776–782
   PubMed Web of Science ®Google Scholar
• Kitajka K, Puskas LG, Zvara A, Hackler L, Barcelo-Coblijn G, Yeo YK, et al. The role of n-3 polyunsaturated fatty acids in brain: Modulation of rat brain gene expression by dietary n-3 fatty acids. Proceedings of the National Academy of Sciences USA 2002; 99: 2619–2624
   PubMed Web of Science ®Google Scholar
• Kivipelto M, Helkala EL, Laakso MP, Hanninen T, Hallikainen M, Alhainen K, et al. Midlife vascular risk factors and Alzheimer's disease in later life: Longitudinal, population based study. British Medical Journal 2001; 322: 1447–1451
   PubMed Web of Science ®Google Scholar
• Klein J. Membrane breakdown in acute and chronic neurodegeneration: Focus on choline-containing phospholipids. Journal of Neural Transmission 2000; 107: 1027–1063
   PubMed Web of Science ®Google Scholar
• Kolsch H, Heun R, Kerksiek A, Bergmann KV, Maier W, Lutjohann D. Altered levels of plasma 24S- and 27-hydroxycholesterol in demented patients. Neuroscience Letters 2004; 368: 303–308
   PubMed Web of Science ®Google Scholar
• Koudinov AR, Koudinova NV. Cholesterol, synaptic function and Alzheimer's disease. Pharmacopsychiatry 2003; 36(Suppl 2)S107–S112
   Google Scholar
• Kyle DJ, Schaefer E, Patton G, Beiser A. Low serum docosahexaenoic acid is a significant risk factor for Alzheimer's dementia. Lipids 1999; 34: S245
   PubMed Web of Science ®Google Scholar
• Laurin D, Verreault R, Lindsay J, Dewailly E, Holub BJ. Omega-3 fatty acids and risk of cognitive impairment and dementia. Journal of Alzheimer's Disease 2003; 5: 315–322
   PubMed Web of Science ®Google Scholar
• Leeson CP, Whincup PH, Cook DG, Mullen MJ, Donald AE, Seymour CA, et al. Cholesterol and arterial distensibility in the first decade of life: A population-based study. Circulation 2000; 101: 1533–1538
   PubMed Web of Science ®Google Scholar
• Leibson CL, Rocca WA, Hanson VA, Cha R, Kokmen E, O’Brien PC, et al. Risk of dementia among persons with diabetes mellitus: A population-based cohort study. American Journal of Epidemiology 1997; 145: 301–308
   PubMed Web of Science ®Google Scholar
• Levine JW, Thompson TE, Barenholz Y, Huang C. Two types of hydroxarbon chain interdigitation in sphingomyelin bilayers. Biochemistry 1985; 24: 6282–6286
   PubMedGoogle Scholar
• Li G, Shofer JB, Kukull WA, Peskind ER, Tsuang DW, Breitner JC, et al. Serum cholesterol and risk of Alzheimer disease: A community-based cohort study. Neurology 2005; 65: 1045–1050
   PubMed Web of Science ®Google Scholar
• Lightle SA, Oakley JI, Nikolova-Karakashian MN. Activation of sphingolipid turnover and chronic generation of ceramide and sphingosine in liver during aging. Mechanisms of Ageing and Development 2000; 120: 111–125
   PubMed Web of Science ®Google Scholar
• Lovell MA, Ehmann WD, Mattson MP, Markesbery WR. Elevated 4-hydroxynonenal in ventricular fluid in Alzheimer's disease. Neurobiology of Aging 1997; 18: 457–461
   PubMed Web of Science ®Google Scholar
• Lutjohann D, Breuer O, Ahlborg G, Nennesmo I, Siden A, Diczfalusy U, et al. Cholesterol homeostasis in human brain: Evidence for an age-dependent flux of 24S-hydroxycholesterol from the brain into the circulation. Proceedings of the National Academy of Sciences USA 1996; 93: 9799–9804
   PubMed Web of Science ®Google Scholar
• Lutjohann D, Papassotiropoulos A, Bjorkhem I, Locatelli S, Bagli M, Oehring RD, et al. Plasma 24S-hydroxycholesterol (cerebrosterol) is increased in Alzheimer and vascular demented patients. Journal of Lipid Research 2000; 41: 195–198
   PubMed Web of Science ®Google Scholar
• Markesbery WR, Carney JM. Oxidative alterations in Alzheimer's disease. Brain Pathology 1999; 9: 133–146
   PubMed Web of Science ®Google Scholar
• Markesbery WR, Lovell MA. Four-hydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimer's disease. Neurobiology of Aging 1998; 19: 33–36
   PubMed Web of Science ®Google Scholar
• Mauch DH, Nagler K, Schumacher S, Goritz C, Muller EC, Otto A, et al. CNS synaptogenesis promoted by glia-derived cholesterol. Science 2001; 294: 1354–1357
   PubMed Web of Science ®Google Scholar
• Mayeux R. Putative risk factors for Alzheimer's disease. Alzheimer's Disease: Cause(s), Diagnosis, Treatment, and Care, Z Khachaturian, TS Radebaugh. CRC Press, Inc, Boca Raton 1996; 39–49
   Google Scholar
• McGrath LT, McGleenon BM, Brennan S, McColl D, McIlroy S, Passmore AP. Increased oxidative stress in Alzheimer's disease as assessed with 4-hydroxynonenal but not malondialdehyde. QJM: monthly journal of the Association of Physicians 2001; 94: 485–490
   PubMed Web of Science ®Google Scholar
• Merrill AH, Jones DD. An update of the enzymology and regulation of sphingomyelin metabolism. Biochimica et Biophysica Acta 1990; 1044: 1–12
   PubMed Web of Science ®Google Scholar
• Merrill AH, Schmelz EM, Dillehay DL, Spiegel S, Shayman JA, Schroeder JJ, et al. Sphingolipids—the enigmatic lipid class: Biochemistry, physiology, and pathophysiology. Toxicology and Applied Pharmacology 1997; 142: 208–225
   PubMed Web of Science ®Google Scholar
• Miatto O, Gonzalez RG, Buonanno F, Growdon JH. In vitro 31P NMR spectroscopy detects altered phospholipid metabolism in Alzheimer's disease. Canadian Journal of Neurological Sciences 1986; 13: 535–539
   PubMedGoogle Scholar
• Mielke MM, Zandi PP, Sjogren M, Gustafson D, Ostling S, Steen B, et al. High total cholesterol levels in late life associated with a reduced risk of dementia. Neurology 2005; 64: 1689–1695
   PubMed Web of Science ®Google Scholar
• Montine TJ, Beal MF, Cudkowicz ME, O’Donnell H, Margolin RA, McFarland L, et al. Increased CSF F2-isoprostane concentration in probable AD. Neurology 1999a; 52: 562–565
   PubMed Web of Science ®Google Scholar
• Montine TJ, Markesbery WR, Zackert W, Sanchez SC, Roberts LJ, Morrow JD. The magnitude of brain lipid peroxidation correlates with the extent of degeneration but not with density of neuritic plaques or neurofibrillary tangles or with APOE genotype in Alzheimer's disease patients. American Journal of Pathology 1999b; 155: 863–868
   PubMed Web of Science ®Google Scholar
• Montine TJ, Quinn JF, Milatovic D, Silbert LC, Dang T, Sanchez S, et al. Peripheral F2-isoprostanes and F4-neuroprostanes are not increased in Alzheimer's disease. Annals of Neurology 2002; 52: 175–179
   PubMed Web of Science ®Google Scholar
• Montine TJ, Shinobu L, Montine KS, Roberts LJ, Kowall NW, Beal MF, et al. No difference in plasma or urinary F2-isoprostanes among patients with Huntington's disease or Alzheimer's disease and controls. Annals of Neurology 2000; 48: 950
   PubMed Web of Science ®Google Scholar
• Morris MC, Evans DA, Bienias JL, Tangney CC, Bennett DA, Wilson RS, et al. Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease. Archives of Neurology 2003; 60: 940–946
   PubMed Web of Science ®Google Scholar
• Mulder C, Wahlund LO, Teerlink T, Blomberg M, Veerhuis R, van Kamp GJ, et al. Decreased lysophosphatidylcholine/phosphatidylcholine ratio in cerebrospinal fluid in Alzheimer's disease. Journal of Neural Transmission 2003; 110: 949–955
   PubMed Web of Science ®Google Scholar
• Mulder M, Ravid R, Swaab DF, de Kloet ER, Haasdijk ED, Julk J, et al. Reduced levels of cholesterol, phospholipids, and fatty acids in cerebrospinal fluid of Alzheimer disease patients are not related to apolipoprotein E4. Alzheimer Disease and Associated Disorders 1998; 12: 198–203
   PubMed Web of Science ®Google Scholar
• Nathan BP, Bellosta S, Sanan DA, Weisgraber KH, Mahley RW, Pitas RE. Differential effects of apolipoproteins E3 and E4 on neuronal growth in vitro. Science 1994; 264: 850–852
   PubMed Web of Science ®Google Scholar
• Needham D, Nunn RS. Elastic deformation and failure of lipid bilayer membranes containing cholesterol. Biophysical Journal 1990; 58: 997–1009
   PubMed Web of Science ®Google Scholar
• Nitsch RM, Blusztajn JK, Pittas AG, Slack BE, Growdon JH, Wurtman RJ. Evidence for a membrane defect in Alzheimer disease brain. Proceedings of the National Academy of Sciences USA 1992; 89: 1671–1675
   PubMed Web of Science ®Google Scholar
• Notkola IL, Sulkava R, Pekkanen J, Erkinjuntti T, Ehnholm C, Kivinen P, et al. Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease. Neuroepidemiology 1998; 17: 14–20
   PubMed Web of Science ®Google Scholar
• Obeid LM, Linardic CM, Karolak LA, Hannun YA. Programmed cell death induced by ceramide. Science 1993; 259: 1769–1771
   PubMed Web of Science ®Google Scholar
• Ott A, Breteler MM, de Bruyne MC, van Harskamp F, Grobbee DE, Hofman A. Atrial fibrillation and dementia in a population-based study. The Rotterdam Study. Stroke 1997; 28: 316–321
   PubMed Web of Science ®Google Scholar
• Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A, Breteler MM. Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology 1999; 53: 1937–1942
   PubMed Web of Science ®Google Scholar
• Papassotiropoulos A, Lutjohann D, Bagli M, Locatelli S, Jessen F, Buschfort R, et al. 24S-hydroxycholesterol in cerebrospinal fluid is elevated in early stages of dementia. Journal of Psychiatric Research 2002; 36: 27–32
   PubMed Web of Science ®Google Scholar
• Papassotiropoulos A, Lutjohann D, Bagli M, Locatelli S, Jessen F, Rao ML, et al. Plasma 24S-hydroxycholesterol: A peripheral indicator of neuronal degeneration and potential state marker for Alzheimer's disease. NeuroReport 2000; 11: 1959–1962
   PubMed Web of Science ®Google Scholar
• Papassotiropoulos A, Streffer JR, Tsolaki M, Schmid S, Thal D, Nicosia F, et al. Increased brain beta-amyloid load, phosphorylated tau, and risk of Alzheimer disease associated with an intronic CYP46 polymorphism. Archives of Neurology 2003; 60: 29–35
   PubMedGoogle Scholar
• Papassotiropoulos A, Wollmer MA, Tsolaki M, Brunner F, Molyva D, Lutjohann D, et al. A cluster of cholesterol-related genes confers susceptibility for Alzheimer's disease. Journal of Clinical Psychiatry 2005; 66: 940–947
   PubMed Web of Science ®Google Scholar
• Park IH, Hwang EM, Hong HS, Boo JH, Oh SS, Lee J, et al. Lovastatin enhances Abeta production and senile plaque deposition in female Tg2576 mice. Neurobiology of Aging 2003; 24: 637–643
   PubMed Web of Science ®Google Scholar
• Pettegrew JW, Panchalingam K, Hamilton RL, McClure RJ. Brain membrane phospholipid alterations in Alzheimer's disease. Neurochemical Research 2001; 26: 771–782
   PubMedGoogle Scholar
• Pettegrew JW, Panchalingam K, Moossy J, Martinez J, Rao G, Boller F. Correlation of phosphorus-31 magnetic resonance spectroscopy and morphologic findings in Alzheimer's disease. Archives of Neurology 1988; 45: 1093–1096
   PubMedGoogle Scholar
• Pitas RE, Boyles JK, Lee SH, Hui D, Weisgraber KH. Lipoproteins and their receptors in the central nervous system. Characterization of the lipoproteins in cerebrospinal fluid and identification of apolipoprotein B, E(LDL) receptors in the brain. Journal of Biological Chemistry 1987; 262: 14352–14360
   PubMed Web of Science ®Google Scholar
• Poirier J, Davignon J, Bouthillier D, Kogan S, Bertrand P, Gauthier S. Apolipoprotein E polymorphism and Alzheimer's disease. Lancet 1993; 342: 697–699
   PubMed Web of Science ®Google Scholar
• Porter NA, Caldwell SE, Mills KA. Mechanisms of free radical oxidation of unsaturated lipids. Lipids 1995; 30: 277–290
   PubMed Web of Science ®Google Scholar
• Pratico D, Clark CM, Lee VM, Trojanowski JQ, Rokach J, FitzGerald GA. Increased 8,12-iso-iPF2alpha-VI in Alzheimer's disease: Correlation of a non-invasive index of lipid peroxidation with disease severity. Annals of Neurology 2000; 48: 809–812
   PubMed Web of Science ®Google Scholar
• Pratico D, Clark CM, Liun F, Rokach J, Lee VY, Trojanowski JQ. Increase of brain oxidative stress in mild cognitive impairment: A possible predictor of Alzheimer disease. Archives of Neurology 2002; 59: 972–976
   PubMedGoogle Scholar
• Pratico D, Delanty N. Oxidative injury in diseases of the central nervous system: Focus on Alzheimer's disease. The American Journal of Medicine 2000; 109: 577–585
   PubMed Web of Science ®Google Scholar
• Pratico D, Li V, Trojanowski JQ, Rokach J, Fitzgerald GA. Increased F2-isoprostanes in Alzheimer's disease: Evidence for enhanced lipid peroxidation in vivo. FASEB Journal 1998; 12: 1777–1783
   PubMed Web of Science ®Google Scholar
• Puskas LG, Kitajka K, Nyakas C, Barcelo-Coblijn G, Farkas T. Short-term administration of omega 3 fatty acids from fish oil results in increased transthyretin transcription in old rat hippocampus. Proceedings of the National Academy of Sciences USA 2003; 100: 1580–1585
   PubMedGoogle Scholar
• Rapoport SI. In vivo fatty acid incorporation into brain phosholipids in relation to plasma availability, signal transduction and membrane remodeling. Journal of Molecular Neuroscience 2001; 16: 243–261
   PubMed Web of Science ®Google Scholar
• Reitz C, Tang MX, Luchsinger J, Mayeux R. Relation of plasma lipids to Alzheimer disease and vascular dementia. Archives of Neurology 2004; 61: 705–714
   PubMed Web of Science ®Google Scholar
• Roberts LJ, Morrow JD. Measurement of F(2)-isoprostanes as an index of oxidative stress in vivo. Free Radical Biology and Medicine 2000; 28: 505–513
   PubMed Web of Science ®Google Scholar
• Romas SN, Tang MX, Berglund L, Mayeux R. APOE genotype, plasma lipids, lipoproteins, and AD in community elderly. Neurology 1999; 53: 517–521
   PubMed Web of Science ®Google Scholar
• Ruvolo PP. Intracellular signal transduction pathways activated by ceramide and its metabolites. Pharmacological Research 2003; 47: 383–392
   PubMed Web of Science ®Google Scholar
• Satoi H, Tomimoto H, Ohtani R, Kitano T, Kondo T, Watanabe M, et al. Astroglial expression of ceramide in Alzheimer's disease brains: A role during neuronal apoptosis. Neuroscience 2005; 130: 657–666
   PubMed Web of Science ®Google Scholar
• Schonknecht P, Lutjohann D, Pantel J, Bardenheuer H, Hartmann T, von Bergmann K, et al. Cerebrospinal fluid 24S-hydroxycholesterol is increased in patients with Alzheimer's disease compared to healthy controls. Neuroscience Letters 2002; 324: 83–85
   PubMed Web of Science ®Google Scholar
• Simons K, Ikonen E. How cells handle cholesterol. Science 2000; 290: 1721–1726
   PubMed Web of Science ®Google Scholar
• Simons M, Keller P, De Strooper B, Beyreuther K, Dotti CG, Simons K. Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proceedings of the National Academy of Sciences USA 1998; 95: 6460–6464
   PubMed Web of Science ®Google Scholar
• Slotte JP. Cholesterol-sphingomyelin interactions in cells—effects on lipid metabolism. Subcellular Biochemistry 1997; 28: 277–293
   PubMedGoogle Scholar
• Snipes G, Suter U. Cholesterol and myelin. Cholesterol, R Bittman. Plenum Press, New York 1998
   Google Scholar
• Stokes CE, Hawthorne JN. Reduced phosphoinositide concentrations in anterior temporal cortex of Alzheimer-diseased brains. Journal of Neurochemistry 1987; 48: 1018–1021
   PubMedGoogle Scholar
• Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, et al. Apolipoprotein E: High-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proceedings of the National Academy of Sciences USA 1993; 90: 1977–1981
   PubMed Web of Science ®Google Scholar
• Svennerholm L, Gottfries CG. Membrane lipids, selectively diminished in Alzheimer brains, suggest synapse loss as a primary event in early-onset form (type I) and demyelination in late-onset form (type II). Journal of Neurochemistry 1994; 62: 1039–1047
   PubMed Web of Science ®Google Scholar
• Tan ZS, Seshadri S, Beiser A, Wilson PW, Kiel DP, Tocco M, et al. Plasma total cholesterol level as a risk factor for Alzheimer disease: The Framingham Study. Archives of Internal Medicine 2003; 163: 1053–1057
   PubMed Web of Science ®Google Scholar
• Teunissen CE, De Vente J, von Bergmann K, Bosma H, van Boxtel MP, De Bruijn C, et al. Serum cholesterol, precursors and metabolites and cognitive performance in an aging population. Neurobiology of Aging 2003; 24: 147–155
   PubMed Web of Science ®Google Scholar
• Urano S, Sato Y, Otonari T, Makabe S, Suzuki S, Ogata M, et al. Aging and oxidative stress in neurodegeneration. Biofactors 1998; 7: 103–112
   PubMed Web of Science ®Google Scholar
• Waddington E, Croft K, Clarnette R, Mori T, Martins R. Plasma F2-Isoprostane levels are increased in Alzheimer's disease: Evidence of increased oxidative stress in vivo. Alzheimer's Report 1999; 2: 277–282
   Google Scholar
• Walter A, Korth U, Hilgert M, Hartmann J, Weichel O, Fassbender K, et al. Glycerophosphocholine is elevated in cerebrospinal fluid of Alzheimer patients. Neurobiology of Aging 2004; 25: 1299–1303
   PubMedGoogle Scholar
• Wechsler A, Brafman A, Shafir M, Heverin M, Gottlieb H, Damari G, et al. Generation of viable cholesterol-free mice. Science 2003; 302: 2087
   PubMed Web of Science ®Google Scholar
• Weiner BH, Ockene IS, Levine PH, Cuenoud HF, Fisher M, Johnson BF, et al. Inhibition of atherosclerosis by cod-liver oil in a hyperlipidemic swine model. New England Journal of Medicine 1986; 315: 841–846
   PubMed Web of Science ®Google Scholar
• Weisgraber KH. Apolipoprotein E: Structure-function relationships. Advances in Protein Chemistry 1994; 45: 249–302
   PubMedGoogle Scholar
• Whitmer RA, Gunderson EP, Barrett-Connor E, Quesenberry CP, Yaffe K. Obesity in middle age and future risk of dementia: A 27 year longitudinal population based study. British Medical Journal 2005a; 330: 1360
   PubMed Web of Science ®Google Scholar
• Whitmer RA, Sidney S, Selby J, Johnston SC, Yaffe K. Midlife cardiovascular risk factors and risk of dementia in late life. Neurology 2005b; 64: 277–281
   PubMed Web of Science ®Google Scholar
• Yaffe K, Kanaya A, Lindquist K, Simonsick EM, Harris T, Shorr RI, et al. The metabolic syndrome, inflammation, and risk of cognitive decline. Journal of the American Medical Association 2004; 292: 2237–2242
   PubMed Web of Science ®Google Scholar
• Yoshitake T, Kiyohara Y, Kato I, Ohmura T, Iwamoto H, Nakayama K, et al. Incidence and risk factors of vascular dementia and Alzheimer's disease in a defined elderly Japanese population: The Hisayama Study. Neurology 1995; 45: 1161–1168
   PubMed Web of Science ®Google Scholar